指南与共识肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

肾超声在显微镜下血尿评估中的诊断性能:验证AUA 2020指南

Assessing the Diagnostic Performance of Renal Ultrasound in Microhematuria Evaluation: Validation of the AUA Microhematuria 2020 Guidelines.
指南 / 共识 · Urology · 2025-09-12

该回顾性研究纳入5167例新发显微镜下血尿患者,评估初始检查中肾超声对泌尿生殖系肿瘤的诊断性能。超声漏诊1例膀胱癌、2例上尿路尿路上皮癌及5例肾癌(1.2%),初始超声阴性后随访影像诊断3例肾癌(0.75%),均为cT1期。结果表明肾超声漏诊或后续诊断癌症率低,支持AUA 2020指南对低中危患者推荐超声。

要点

  • 肾超声在显微镜下血尿初始评估中漏诊或后续癌症诊断率低。
  • 超声漏诊1例膀胱癌、2例上尿路尿路上皮癌及5例肾癌(1.2%)。
  • 初始超声阴性后随访诊断3例肾癌(0.75%),均为cT1期。

核心结论

  • 在大规模显微镜下血尿人群中,肾超声初始检查漏诊或后续癌症诊断率低,支持AUA 2020指南推荐。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月至2018年4月期间新发显微镜下血尿并接受初始影像检查的患者5167例。

主要发现

  • 超声漏诊CT诊断的1例膀胱癌、2例上尿路尿路上皮癌及5例肾癌(1.2%)。
  • 初始超声阴性后随访影像(n=401)诊断3例肾癌(0.75%),中位诊断时间398天,均为cT1期。

临床怎么用

  • 对低中危显微镜下血尿患者,可依据AUA 2020指南采用肾超声进行初始评估。
  • 超声阴性后若出现症状,应进行随访影像检查以及时发现早期肿瘤。

局限性

  • 回顾性研究,来自单一社区医院,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate changes to the American Urological Association Microhematuria guidelines recommending ultrasound for low and intermediate-risk patients instead of cross-sectional imaging, we evaluated the performance of ultrasound in microhematuria evaluation in a large population with a new microhematuria event. METHODS: After Institutional Review Board approval, medical records from a large community hospital were retrospectively queried for patients with new microhematuria and imaging performed during initial workup from January 2015 to April 2018. Follow-up imaging and subsequent diagnoses during the next 5 years (between 2018-2023) were evaluated for missed genitourinary cancer diagnoses. RESULTS: A cohort of 5167 patients with microhematuria underwent imaging during initial workup. Forty-seven cancers were diagnosed on imaging: 32 kidney, 12 bladder, and 3 upper tract cancers. Approximately half of the cohort underwent renal ultrasound during initial workup. Most cancers were diagnosed on cross-sectional imaging. One bladder and 2 upper tract urothelial cancers identified on CT were missed on ultrasound. Five kidney cancers diagnosed on CT were missed on concurrent ultrasound (1.2%). In patients with a negative ultrasound during initial workup with follow-up cross-sectional imaging between 2018 and 2023 (n=401), 3 kidney cancers were diagnosed on subsequent imaging (0.75%). Median time to subsequent diagnosis was 398 days and all masses were cT1. CONCLUSION: In a large microhematuria population, renal ultrasound was frequently performed during initial workup with a rare missed or subsequent cancer diagnosis rate. Subsequent imaging after RUS was typically prompted by the development of symptoms, but follow-up studies showed early-stage disease, suggesting diagnosis was made in a timely fashion.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Bochner E, Ibezue C, Banerji D, et al. Assessing the Diagnostic Performance of Renal Ultrasound in Microhematuria Evaluation: Validation of the AUA Microhematuria 2020 Guidelines. Urology. 2025. PMID: 40946922. doi:10.1016/j.urology.2025.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。